SIGA

SIGA Technologies, Inc. - 10-Q Summary (Period Ended Sept 30, 2010)

Business Context and Reporting Period

SIGA Technologies, Inc. is a bio-defense company focused on the discovery and development of novel products for serious infectious diseases, including smallpox and arenaviruses. The lead product candidate is ST-246, an antiviral for orthopoxviruses. This report covers the quarterly period ended September 30, 2010. The filing includes restated financial data for the prior year (2009) due to an accounting error regarding the fair value of common stock warrants.

Key Financial Metrics

Cash Flow (9 Months 2010): Net cash used in operating activities was $7.4 million. Net cash used in investing activities was $9.3 million (primarily purchases of short-term investments). Net cash provided by financing activities was $7.9 million (proceeds from securities issuance and warrant exercises).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 64% to $16.2 million, driven by increased grants for arenavirus drug candidates ($2.5M increase), the lead drug ST-246 ($2.0M increase), and a broad-spectrum antiviral ($1.7M increase).
• Expense Increases: R&D expenses rose 49% to $18.2 million due to clinical testing and manufacturing validation for ST-246 and increased activity in arenavirus programs. SG&A expenses increased slightly by 4% to $5.6 million.
• Warrant Valuation Impact: The company recorded a $6.1 million loss due to the increase in the fair value of common stock warrants classified as liabilities. This compares to a $13.7 million loss in the prior year (restated).
• Liquidity Position: Cash and short-term investments totaled approximately $19.5 million at period end, up from roughly $6.4 million in the prior year, bolstered by a $5.5 million investment from MacAndrews & Forbes (M&F) in July 2010.

Outlook, Risks, and Contingencies

• Capital Resources: Management believes existing funds and government grants will support operations for at least the next 12 months. However, the company has no commercial products and expects to incur additional losses.
• Government Contracts: The U.S. Department of Health and Human Services (HHS) announced an intention to award SIGA a contract for 1.7 million courses of its smallpox antiviral for the Strategic National Stockpile, pending resolution of Small Business Administration status issues. No assurance of final award terms is provided.
• Legal Proceedings: PharmAthene, Inc. is suing SIGA regarding a license agreement for ST-246, seeking damages up to $1 billion. Trial is expected in January 2011. SIGA believes it has meritorious defenses but cannot estimate a range of loss.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the accounting of warrant anti-dilution provisions, which necessitated the restatement of prior periods. A remediation plan is in progress.

Investor Verification Checklist

• Verify the status of the HHS/BARDA contract award for the Strategic National Stockpile and any remaining regulatory hurdles.
• Monitor the timeline and potential outcome of the PharmAthene litigation, specifically the January 2011 trial date.
• Review the progress of the remediation plan for the material weakness in internal controls over financial reporting.
• Assess the sustainability of the cash burn rate relative to the $19.5 million liquidity position and the timeline for future financing needs.
• Confirm the impact of warrant valuation changes on future earnings, as these are non-cash items that significantly affect net loss.